Work

Phase 1, first-in-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature.

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.tps3105

Authors: Anthony W. Tolcher, Evan W. Alley, Guru Chichili, Jan E. Baughman, Paul A. Moore, Ezio Bonvini, James Robert Vasselli, Jon M. Wigginton, John D. Powderly

Institutions: South Texas Accelerated Research Therapeutics, University of Pennsylvania, MacroGenics (United States), Carolina BioOncology Institute

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2534628219

Cites:

Cited by: 27

Related to: 10